Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 8, 2013, Pages 1124-1134

  Martin, Darryl T ^a   Hoimes, Christopher J ^a,b   Kaimakliotis, Hristos Z ^a   Cheng, Christopher J ^b   Zhang, Ke ^c   Liu, Jingchun ^a   Wheeler, Marcia A ^a   Kelly, W Kevin ^d   Tew, Greg N ^c   Saltzman, W Mark ^b   Weiss, Robert M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale University   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Belinostat; Bladder cancer; Nanoparticle; PLGA; Poly(guanidinium oxanorbornene)

Indexed keywords

BELINOSTAT; BLADDER CANCERS; GUANIDINIUM; HISTONE DEACETYLASE INHIBITOR; PERMEABILITY BARRIERS; PLGA; POLY-LACTIDE-CO-GLYCOLIDE; SURFACE FUNCTIONALIZATION;

BIOACTIVITY; CHEMOTHERAPY; COPOLYMERS; DISEASE CONTROL; DISEASES; DRUG DELIVERY; ENZYME INHIBITION; MAMMALS; NANOPARTICLES; SYNTHESIS (CHEMICAL); TUMORS;

PATIENT TREATMENT;

ACTIN; BELINOSTAT; NANOPARTICLE; POLY(GUANIDINIUM OXANORBORNENE); POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DETRUSOR MUSCLE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG PENETRATION; DRUG RESPONSE; EX VIVO STUDY; FEMALE; HISTONE ACETYLATION; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; INTERNALIZATION; LAMINA PROPRIA; NONHUMAN; PROTEIN EXPRESSION; TUMOR VOLUME; UROTHELIUM; WEIGHT CHANGE;

BELINOSTAT; BLADDER CANCER; NANOPARTICLE; PLGA; POLY(GUANIDINIUM OXANORBORNENE);

ANIMALS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; NANOPARTICLES; POLYGLACTIN 910; SULFONAMIDES; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84886388787     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.05.017     Document Type: Article

References (43)

1. Baffa R., Letko J., McClung C., LeNoir J., Vecchione A., Gomella L.G. Molecular genetics of bladder cancer: targets for diagnosis and therapy. J Exp Clin Cancer Res: CR. 2006, 25:145-160.
2. Alexandroff A.B., Jackson A.M., O'Donnell M.A., James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999, 353:1689-1694.
3. GuhaSarkar S., Banerjee R. Intravesical drug delivery: Challenges, current status, opportunities and novel strategies. J Control Release 2010, 148:147-159.
4. Gurpinar T., Truong L.D., Wong H.Y., Griffith D.P. Electromotive drug administration to the urinary bladder: an animal model and preliminary results. J Urol 1996, 156:1496-1501.
5. Di Stasi S.M., Valenti M., Verri C., et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol 2011, 12:871-879.
6. Di Stasi S.M., Giannantoni A., Stephen R.L., et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003, 170:777-782.
7. Barocas D.A., Globe D.R., Colayco D., et al. Surveillance and treatment of non-muscle-invasive bladder cancer in the USA. Adv Urol 2012, 2012:8.
8. Chiba T., Yokosuka O., Arai M., et al. Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J Hepatol 2004, 41:436-445.
9. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003, 2:151-163.
10. Lee H., Lee S., Baek M., Kim H.-Y., Jeoung D.-I. Expression profile analysis of trichostatin A in human gastric cancer cells. Biotechnol Lett 2002, 24:377-381.
11. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000, 92:1210-1216.
12. Tran A.D.-A., Marmo T.P., Salam A.A., et al. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci 2007, 120:1469-1479.
13. Qian X., Ara G., Mills E., LaRochelle W.J., Lichenstein H.S., Jeffers M. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer J Int du Cancer 2008, 122:1400-1410.
14. Buckley M.T., Yoon J., Yee H., et al. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med 2007, 5:49.
15. Gould J.J., Kenney P.A., Rieger-Christ K.M., et al. Identification of tumor and invasion suppressor gene modulators in bladder cancer by different classes of histone deacetylase inhibitors using reverse phase protein arrays. J Urol 2010, 183:2395-2402.
16. Chowdhury S., Howell G.M., Teggart C.A., et al. Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor β (TGFβ) receptor II leading to cancer cell death. J Biol Chem 2011, 286:30937-30948.
17. Portland VA Medical Center Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation 2013, National Library of Medicine (US), Bethesda (MD), NLM Identifier: NCT01265953.
18. Steele N.L., Plumb J.A., Vidal L., et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008, 14:804-810.
19. Khan A., Benboubetra M., Sayyed P.Z., et al. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J Drug Target 2004, 12:393-404.
20. Anthony T., Fong P., Goyal A., Saltzman W.M., Moss R.L., Breuer C. Development of a parathyroid hormone-controlled release system as a potential surgical treatment for hypoparathyroidism. J Pediatr Surg 2005, 40:81-85.
21. Woodrow K.A., Cu Y., Booth C.J., Saucier-Sawyer J.K., Wood M.J., Saltzman W.M. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 2009, 8:526-533.
22. Cu Y., Booth C.J., Saltzman W.M. In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. J Control Release 2011, 156:258-264.
23. Zhou J., Patel T.R., Fu M., Bertram J.P., Saltzman W.M. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 2012, 33:583-591.
24. Sawyer A.J., Saucier-Sawyer J.K., Booth C.J., et al. Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Delivery Transl Res 2011, 1:34-42.
25. Cheng C.J., Saltzman W.M. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials 2011, 32:6194-6203.
26. Fahmy T.M., Samstein R.M., Harness C.C., Mark Saltzman W. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 2005, 26:5727-5736.
27. Hennig A., Gabriel G.J., Tew G.N., Matile S. Stimuli-responsive polyguanidino-oxanorbornene membrane transporters as multicomponent sensors in complex matrices. J Am Chem Soc 2008, 130:10338-10344.
28. Gabriel G.J., Madkour A.E., Dabkowski J.M., Nelson C.F., Nusslein K., Tew G.N. Synthetic mimic of antimicrobial peptide with nonmembrane-disrupting antibacterial properties. Biomacromolecules 2008, 9:2980-2983.
29. Martin D.T., Steinbach J., Kaimakliotis H., et al. Surface modifications of poly(lactide-co-glycolide) nanoparticles can increase its uptake by bladder cancer cells. J Urol 2011, 185:e424.
30. Takizawa B.T., Uchio E.M., Cohen J.J., Wheeler M.A., Weiss R.M. Downregulation of survivin is associated with reductions in TNF receptors' mRNA and protein and alterations in nuclear factor kappa B signaling in urothelial cancer cells. Cancer Invest 2007, 25:678-684.
31. Martin D.T., Gendron R.L., Jarzembowski J.A., et al. Tubedown expression correlates with the differentiation status and aggressiveness of neuroblastic tumors. Clin Cancer Res 2007, 13:1480-1487.
32. Kuefer R., Hofer M.D., Altug V., et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 2004, 90:535-541.
33. Marquard L., Petersen K.D., Persson M., Hoff K.D., Jensen P.B., Sehested M. Monitoring the effect of belinostat in solid tumors by H4 acetylation. APMIS: Acta pathologica, microbiologica, et immunologica scand 2008, 116:382-392.
34. Urbinati G., Marsaud V., Plassat V., Fattal E., Lesieur S., Renoir J.M. Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy. Int J Pharm 2010, 397:184-193.
35. Do D.P., Pai S.B., Rizvi S.A., D'Souza M.J. Development of sulforaphane-encapsulated microspheres for cancer epigenetic therapy. Int J Pharm 2010, 386:114-121.
36. Seiler M.W., Venkatachalam M.A., Cotran R.S. Glomerular epithelium: structural alterations induced by polycations. Science 1975, 189:390-393.
37. Quinton P.M., Philpott C.W. A role for anionic sites in epithelial architecture. Effects of cationic polymers on cell membrane structure. J Cell Biol 1973, 56:787-796.
38. Lavelle J., Meyers S., Ramage R., et al. Bladder permeability barrier: recovery from selective injury of surface epithelial cells. Am J Physiol Renal Physiol 2002, 283:F242-F253.
39. Muramaki M., Miyake H., Hara I., Kamidono S. Introduction of midkine gene into human bladder cancer cells enhances their malignant phenotype but increases their sensitivity to antiangiogenic therapy. Clin Cancer Res 2003, 9:5152-5160.
40. Tanaka M., Grossman H.B. Connexin 26 gene therapy of human bladder cancer: induction of growth suppression, apoptosis, and synergy with Cisplatin. Hum Gene Ther 2001, 12:2225-2236.
41. Nakahara T., Kita A., Yamanaka K., et al. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 2011, 102:614-621.
42. Hnilicová J., Hozeifi S., Dušková E., Icha J., Tománková T., Staněk D. Histone deacetylase activity modulates alternative splicing. PLoS One 2011, 6:e16727.
43. Plumb J.A., Finn P.W., Williams R.J., et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003, 2:721-728.